The context-specific upregulation of Prkaa2 in tumor-infiltrating Treg cells may explain the discrepant consequences for antitumor immunity reported in Treg cell–specific AMPKα1-deficient mice challenged with B16 melanoma tumors (29, 30). This evidence concerns the gene PRKAA2 and neoplasm.